NKTR Nektar Therapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: NKTR

Price (delayed)

$1.32

Market cap

$242.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.45

Enterprise value

$324.87M

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. ...

Highlights
Nektar Therapeutics's EPS has increased by 26% YoY and by 7% QoQ
The net income has grown by 25% year-on-year and by 6% since the previous quarter
The revenue has grown by 2.1% from the previous quarter but it has contracted by 2.1% YoY
Nektar Therapeutics's equity has shrunk by 64% YoY and by 18% QoQ
Nektar Therapeutics's quick ratio has decreased by 21% YoY and by 17% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nektar.com
Peers: PFE MRK AMGN ENZN

Key stats

What are the main financial stats of NKTR
Market
Shares outstanding
183.62M
Market cap
$242.38M
Enterprise value
$324.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
2.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.6
Earnings
Revenue
$90.12M
EBIT
-$250.92M
EBITDA
-$243.11M
Free cash flow
-$192.23M
Per share
EPS
-$1.45
Free cash flow per share
-$1.01
Book value per share
$0.69
Revenue per share
$0.47
TBVPS
$2.09
Balance sheet
Total assets
$398.03M
Total liabilities
$267.05M
Debt
$117.78M
Equity
$130.99M
Working capital
$279.43M
Liquidity
Debt to equity
0.9
Current ratio
6.45
Quick ratio
5.95
Net debt/EBITDA
-0.34
Margins
EBITDA margin
-269.8%
Gross margin
62.5%
Net margin
-306.3%
Operating margin
-292.6%
Efficiency
Return on assets
-58.2%
Return on equity
-151.6%
Return on invested capital
-51.6%
Return on capital employed
-72.4%
Return on sales
-278.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
-4.35%
1 week
0%
1 month
48.63%
1 year
70.06%
YTD
133.63%
QTD
41.3%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$90.12M
Gross profit
$56.35M
Operating income
-$263.68M
Net income
-$276.06M
Gross margin
62.5%
Net margin
-306.3%
The operating income is up by 30% year-on-year and by 7% since the previous quarter
The operating margin has grown by 28% YoY and by 9% from the previous quarter
The net income has grown by 25% year-on-year and by 6% since the previous quarter
The net margin has increased by 23% YoY and by 8% QoQ

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
2.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.6
Nektar Therapeutics's EPS has increased by 26% YoY and by 7% QoQ
The P/B is 174% above the last 4 quarters average of 0.7 but 17% below the 5-year quarterly average of 2.3
Nektar Therapeutics's equity has shrunk by 64% YoY and by 18% QoQ
The stock's P/S is 114% more than its last 4 quarters average of 1.3 but 85% less than its 5-year quarterly average of 18.3
The revenue has grown by 2.1% from the previous quarter but it has contracted by 2.1% YoY

Efficiency

How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's ROE has plunged by 90% YoY and by 24% from the previous quarter
NKTR's ROA is down by 33% YoY and by 9% from the previous quarter
Nektar Therapeutics's return on sales has increased by 24% YoY and by 7% QoQ
The return on invested capital has declined by 12% year-on-year and by 3.4% since the previous quarter

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 49% more than its total liabilities
Nektar Therapeutics's total assets has decreased by 44% YoY and by 10% from the previous quarter
The total liabilities has contracted by 22% YoY and by 6% from the previous quarter
The debt is 10% lower than the equity
The debt to equity has soared by 150% YoY and by 18% QoQ
Nektar Therapeutics's equity has shrunk by 64% YoY and by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.